Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Putnam and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Putnam is a boutique strategy consulting firm dedicated exclusively to the life sciences industry, including biopharmaceuticals, biotechnology, medical devices, and diagnostics. The firm provides strategic advice and analytical services to help clients navigate complex business decisions across the entire product lifecycle, from early-stage development to loss of exclusivity. In 2021, the firm rebranded as Putnam and is now part of Inizio Ignite (formerly Inizio Advisory), a global advisory partner for health and life sciences. Putnam serves a diverse client base, including the majority of the top 20 global biopharmaceutical organizations, emerging biotech companies, and private equity/venture capital firms.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:CRO
Sub-Industry:Strategy Consulting
SIZE & FINANCIALS
Employees:201-500
Revenue:$25M-$100M
Founded:1988
Ownership:subsidiary
Status:operating
0
CORPORATE STRUCTURE
Parent Company:Inizio
Acquired By:Inizio (formerly UDG Healthcare)
Key Partnerships:Research Partnership, STEM, Vynamic
COMPETITION
Position:Leader
Competitors:L.E.K. Consulting, ClearView Healthcare Partners, Trinity Life Sciences
LEADERSHIP
Key Executives:
Remco op den Kelder - CEO
Scientific Founders:Bill Putnam, Richard McFarland, Dennis Swinford
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Putnam. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.